Type 2 Diabetes Mellitus Clinical Trial
— HMHBOfficial title:
Healthy Moms, Healthy Babies: A Strategy to Improve the Care and OUtcome of Diabetes in Pregnancy in On-Reserve First Nations Women
Verified date | March 2017 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Poor glucose control during pregnancy is a significant concern for Canadian women with
diabetes. This problem is magnified in First Nations women, who have among the highest rates
of gestational diabetes (GDM) in the world (up to 18% of First Nations women will develop
GDM during pregnancy and 70% of these will go on to develop type 2 diabetes later).
Continuous glucose monitoring (CGM) technology has the potential to help women maintain
tighter control during pregnancy, however, in the First Nations population, there are many
unique barriers that may affect use of this technology. Such barriers include remoteness of
the community, cultural apprehension, lack or difficulty of access to care, and language
differences.
A total of 60 participants from three participating First Nations communities in Southern
Ontario will participate in the study. Participants will self-select to either the CGM group
(n=30) or the control group (n=30) after consenting to participate in the study.
Participants in both groups will be asked to monitor their blood glucose for 5 days for the
28th, 32nd and 36th week of gestation. Primary outcomes to be evaluated include maternal A1c
and offspring birth weight. To assess the feasibility and acceptability of CGMs among First
Nations women, a questionnaire will be distributed to participants to gather insight into
their rationale for enrolling into either group. Recruitment rates for both groups will also
be used to assess feasibility and acceptability of CGMs. Additionally, all participants will
be encouraged to participate in a community lifestyle program consisting of 30-min exercise
sessions offered five days a week. The community lifestyle program will be adapted to the
community, linked to existing programs with support from program personnel and will include
educational sessions related to diabetes and healthy lifestyles. It is hypothesized that
through participation in the community lifestyle program, pregnant First Nations women with
diabetes will experience a decrease in their blood glucose values post-exercise, mitigate
excessive weight gain and normalize their A1c's. It is further hypothesized that an increase
in women's regular physical activity levels, the number of steps taken and knowledge of
diabetes will be observed.
Status | Completed |
Enrollment | 18 |
Est. completion date | August 29, 2014 |
Est. primary completion date | August 29, 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - First Nations (self-identified) - On-reserve (living or receiving care) - Informed consent to participate - Adults aged 18 years or older - Diagnosed with gestational diabetes (GDM) or type 2 diabetes (T2DM) - Pregnant (less than or equal to 36 weeks o gestation) - Consent to have primary care giver informed of participation in teh project - Willingness to perform required study and data collectin procedures and adhere to the operating requirements of the iPro2 and/or the glucose meter - Willingness to wear the iPro 2 continuous glucose monitor (CGM) for 5 days for the 28th, 32nd, 36th week of pregnancy (for participants in the CGM group) - Willingness to perform at least 4 finger prick testing per day during the Monitoring Week of the 28th, 32nd, 36th week of pregnancy (for CGM and control group) Exclusion Criteria: - Lack of decision making capacity to provide consent - Participating in another diabetes and/or lifestyle improvement research project - Non-First Nations descent - Pregnant diagnosed with type 1 diabetes - Pregnant not diagnosed with GDM or T2DM - Pregnant women past 36th week of gestation - Participants who do not consent to have their primary care giver informed of project participation - The participant has a history of tape allergies that have not been resolved - The participant has any skin abnormality (e.g. Psoriasis, rash, staphylococcus infection) that has not been resolved and would inhibit her from wearing the sensor - Any other condition (s) that in the Investigator's opinion would warrant exclusion from the study or prevent the participant from completing the project |
Country | Name | City | State |
---|---|---|---|
Canada | Western University | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Stewart Harris | Juvenile Diabetes Research Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maternal HbA1c | Lab collected at the specific time periods listed above. | 24, 28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014 | |
Primary | Offspring Birth Weight | Offspring birth weight will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | 1 hour post-prandial glucose measurements (maternal) | This will be collected from the CGM or glucose meter, depending on the group the participant consents to take part in. | 28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014. | |
Secondary | Weight gain (maternal) | Baseline weight is collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms). Follow-up weight measurements are done at each visit until delivery. Weight gain is calculated from the baseline and follow-up measurements. | Weight is recorded at each visit from May 2012 to September 2014. | |
Secondary | Maternal diabetes treatment | Baseline treatment will be collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms) if available. | 28, 32, and 36 weeks of gestation. This will occur between May 2012 to September 2014. | |
Secondary | Daily mean glucose values (maternal) | This will be calculated from the glucose measurements taken using either the CGM or the glucose meter. | 28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014. | |
Secondary | Insulin Use (maternal) | Baseline insulin use will be collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms) if available. | 24, 28, 32, and 36 weeks of gestation. This will occur between May 2012 to September 2014. | |
Secondary | Neonatal gestational age | Neonatal gestational age will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Neonatal hypoglycemia | Neonatal hypoglycemia will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2013. | |
Secondary | Neonatal Intensive Care Unit (NICU) Admission | This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Number of days in the hospital (neonatal) | This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Birth injuries (neonatal) | This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Jaundice (neonatal) | This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Delivery in a community or teaching hospital | This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Caesarean section rate (maternal) | This will be collected from the Neonatal Examination Form/Birth Record and Maternal Discharge Summary. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Delivery Methods | Forceps, vacuum-assisted. This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Cephalopelvic disproportion | This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Number of days in hospital post delivery (maternal) | This will be collected from the Maternal Discharge Summary. | At Delivery. This will occur between May 2012 to September 2014. | |
Secondary | Shoulder Dystocia (neonatal) | This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries. | At Delivery. This will occur between May 2012 to September 2014. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |